Skip to content
Biodatica
Start free

Ascentage Pharma Group Inc.

Guangzhou, Guangdong

Oncologycell therapyPhase III
Compare Sign in to watch

What changed

Phase II trial registered: Doxorubicin Hydrochloride Liposome Combined With Irinotecan (AI Regimen) Versus VIT Regimen in the Treatment of Relapsed and Refractory Pediatric Rhabdomyosarcoma: a Prospective, Open-label, Randomized Controlled, Multicenter, Phase II Clinical Study

2mo agoTrial registeredMay 18, 2026Source filing (opens the source filing in a new tab)

Momentum

76no change

Momentum 76 out of 100, unchanged since the last recompute.

Accelerating: several high-weight events landed recently.

Runway (estimate)

—unknown

No disclosed raise on file, so there is nothing to model from.

Stage

Phase III

The furthest-along thing in the public record. Not a projection.

Runway is an estimate: the last disclosed raise (SEC Form D) minus a modeled burn rate for the company’s stage and therapeutic area. It is not a disclosure, and companies routinely raise non-dilutive money we can’t see. How this is calculated.

Peer position

239 pre-ticker oncology companies at Phase III

Peer ranking — where this company sits among its stage-and-area peers by momentum, and how its runway compares to the peer median — is part of the Analyst tier.

Compare seats

A ranking of the same momentum figure the feed publishes, computed live against public-filing peers. It is a relative position, not a recommendation, and it is identical for every viewer.

Grant to raise

Every record Biodatica has resolved onto this company, newest first, each linked to the filing it came from. Where a source publishes no stable deep link for a record, the identifier is shown so you can look it up yourself.

  1. Trial

    NA registered

    Nov 1, 2024

    Soft Tissue Sarcoma (STS) · RECRUITING · sponsor: Sun Yat-sen University · Umbilical Cord Blood NK Cell Therapy for High-Risk Pediatric Soft Tissue Sarcoma: Efficacy and Safety Study

    ClinicalTrials.gov · NCT06848582 (opens the source filing in a new tab)

  2. Trial

    PHASE2 registered

    Dec 30, 2023

    Rhabdomyosarcoma, Child · RECRUITING · sponsor: Sun Yat-sen University · Doxorubicin Hydrochloride Liposome Combined With Irinotecan (AI Regimen) Versus VIT Regimen in the Treatment of Relapsed and Refractory Pediatric Rhabdomyosarcoma: a Prospective, Open-label, Randomized Controlled, Multicenter, Phase II Clinical Study

    ClinicalTrials.gov · NCT05457829 (opens the source filing in a new tab)

  3. Trial

    PHASE1 registered

    Feb 28, 2023

    Neuroblastoma, Solid Tumor · RECRUITING · sponsor: Ascentage Pharma Group Inc. · APG-115 Alone or in Combination With APG-2575 in Children With Recurrent or Refractory Neuroblastoma or Solid Tumors

    ClinicalTrials.gov · NCT05701306 (opens the source filing in a new tab)

  4. Trial

    PHASE3 registered

    Jan 30, 2017

    Rhabdomyosarcoma, Pediatric Cancer · RECRUITING · sponsor: Yizhuo Zhang · A Prospective Clinical Cohort Study on Stratified Treatment of Rhabdomyosarcoma Based on Risk Factors.

    ClinicalTrials.gov · NCT06836492 (opens the source filing in a new tab)

Biodatica publishes impersonal research shown identically to every subscriber. This dossier is informational only, it is not investment advice, and the momentum and runway figures are estimates derived from public filings. The underlying records are U.S. government works. Disclosures · Data sources